Expert Review of Hematology

Papers
(The H4-Index of Expert Review of Hematology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome67
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care56
What is the future of digital tools to help manage pain in sickle cell disease patients?43
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP42
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon37
Treatment patterns and blood count control in 10,112 patients with polycythemia vera33
Do we need more guidance on thrombophilia testing? Challenges and special considerations27
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease25
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic l24
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management24
Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management24
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future23
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective20
Correlation between hematocrit and the risk of common human cancers: results of a 1999–2020 observational survey and Mendelian randomization analysis19
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B19
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia18
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations18
Improving endpoints for sickle cell disease clinical trials: retaining consistency and clinical benefit18
0.073247194290161